93 results on '"Samur M"'
Search Results
2. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer
- Author
-
Bouillez, A, Rajabi, H, Jin, C, Samur, M, Tagde, A, Alam, M, Hiraki, M, Maeda, T, Hu, X, Adeegbe, D, Kharbanda, S, Wong, K-K, and Kufe, D
- Published
- 2017
- Full Text
- View/download PDF
3. Nucleotide excision repair is a potential therapeutic target in multiple myeloma
- Author
-
Szalat, R, Samur, M K, Fulciniti, M, Lopez, M, Nanjappa, P, Cleynen, A, Wen, K, Kumar, S, Perini, T, Calkins, A S, Reznichenko, E, Chauhan, D, Tai, Y-T, Shammas, M A, Anderson, K C, Fermand, J-P, Arnulf, B, Avet-Loiseau, H, Lazaro, J-B, and Munshi, N C
- Published
- 2018
- Full Text
- View/download PDF
4. Does awareness of diagnosis make any difference to quality of life?: Determinants of emotional functioning in a group of cancer patients in Turkey
- Author
-
Bozcuk, H., Erdoğan, V., Eken, C., Çıplak, E., Samur, M., Özdoğan, M., and Savaş, B.
- Published
- 2002
- Full Text
- View/download PDF
5. Predictors of distant metastasis at presentation in breast cancer: a study also evaluating associations among common biological indicators
- Author
-
Bozcuk, H., Uslu, G., Peştereli, E., Samur, M., Ozdoğan, M., Karaveli, Ş, Sargın, F., and Savaş, B.
- Published
- 2001
- Full Text
- View/download PDF
6. The effect of two different doses of oral clodronate on pain in patients with bone metastases
- Author
-
Arican, A, İçli, F, Akbulut, H, Çakir, M, Şencan, O, Samur, M, Açikgöz, N, and Demirkazik, A
- Published
- 1999
- Full Text
- View/download PDF
7. A simple and accurate prediction model to estimate the intrahospital mortality risk of hospitalised cancer patients
- Author
-
BOZCUK, H., KOYUNCU, E., YILDIZ, M., SAMUR, M., ÖZDOǦAN, M., ARTAÇ, M., ÇOBAN, E., and SAVAŞ, B.
- Published
- 2004
8. Expressed fusion gene landscape and its impact in multiple myeloma.
- Author
-
Cleynen, A., Szalat, R., Samur, M. Kemal, du Pont, S. Robiou, Buisson, L., Boyle, E., Chretien, M.L., Anderson, K., Minvielle, S., Moreau, P., Attal, M., Parmigiani, G., Corre, J., Munshi, N., and Avet-Loiseau, H.
- Abstract
Multiple myeloma is a plasma cell malignancy characterized by recurrent IgH translocations and well described genomic heterogeneity. Although transcriptome profiles in multiple myeloma has been described, landscape of expressed fusion genes and their clinical impact remains unknown. To provide a comprehensive and detailed fusion gene cartography and suggest new mechanisms of tumorigenesis in multiple myeloma, we performed RNA sequencing in a cohort of 255 newly diagnosed and homogeneously treated multiple myeloma patients with long follow-up. Here, we report that patients have on average 5.5 expressed fusion genes. Kappa and lambda light chains and IgH genes are main partners in a third of all fusion genes. We also identify recurrent fusion genes that significantly impact both progression-free and overall survival and may act as drivers of the disease. Lastly, we find a correlation between the number of fusions, the age of patients and the clinical outcome, strongly suggesting that genomic instability drives prognosis of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. P881: CDK7 CONTRIBUTES TO METABOLIC REPROGRAMMING IN MM CELLS THROUGH C‐MYC MEDIATED TRANSCRIPTIONAL CONTROL OF GLYCOLYTIC GENES.
- Author
-
Yao, Y., Fong Ng, J., Park, W. D., Gramegna, D., Samur, A., Samur, M., Morelli, E., Chesi, M., Mitsiades, C., Anderson, K. C., Lin, C., Munshi, N., and Fulciniti, M.
- Published
- 2022
- Full Text
- View/download PDF
10. Evaluation of the Usability of a Serious Game Aiming to Teach Facial Expressions to Schizophrenic Patients.
- Author
-
ISLEYEN, Filiz, GULKESEN, K. Hakan, CINEMRE, Buket, SAMUR, M. Kemal, ZAYIM, Nese, and SEN KAYA, Semiha
- Abstract
In some psychological disorders such as autism and schizophrenia, loss of facial expression recognition skill may complicate patient's daily life. Information technology may help to develop facial expression recognition skill by educational software and games. We designed and developed an interactive webbased educational program with which we performed a usability study before investigating its effectiveness on the schizophrenia patients' ability of emotion perception. The purpose of this study is to describe the usability evaluation for a web-based game set that has been designed to teach facial expressions to schizophrenic patients. The usability study was done at two steps; first, we applied heuristic evaluation and the violations were rated in a scale from most to least severe and the major problems were solved. In the second step, think-aloud method was used and the web site was assessed by five schizophrenic patients. Eight experts participated in the heuristic evaluation, in which a total of 60 violations were identified with a mean severity of 2.77 (range: 0-4). All of the major problems (severity over 2.5) were listed and the usability problems were solved by the development team. After solving the problems, five users with a diagnosis of schizophrenia used the web site with the same scenario. They reported to have experienced minor, but different problems. In conclusion, we suggest that a combination of heuristic evaluation and think-aloud method may be an effective and efficient way for usability evaluations for the serious games that have been designed for special patient groups. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth
- Author
-
Fulciniti, M, Amodio, N, Bandi, R L, Cagnetta, A, Samur, M K, Acharya, C, Prabhala, R, D'Aquila, P, Bellizzi, D, Passarino, G, Adamia, S, Neri, A, Hunter, Z R, Treon, S P, Anderson, K C, Tassone, P, and Munshi, N C
- Abstract
Deregulated microRNA (miR)/transcription factor (TF)-based networks represent a hallmark of cancer. We report here a novel c-Myc/miR-23b/Sp1 feed-forward loop with a critical role in multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) cell growth and survival. We have found miR-23b to be downregulated in MM and WM cells especially in the presence of components of the tumor bone marrow milieu. Promoter methylation is one mechanism of miR-23b suppression in myeloma. In gain-of-function studies using miR-23b mimics-transfected or in miR-23b-stably expressing MM and WM cell lines, we observed a significant decrease in cell proliferation and survival, along with induction of caspase-3/7 activity over time, thus supporting a tumor suppressor role for miR-23b. At the molecular level, miR-23b targeted Sp1 3′UTR and significantly reduced Sp1-driven nuclear factor-κB activity. Finally, c-Myc, an important oncogenic transcription factor known to stimulate MM cell proliferation, transcriptionally repressed miR-23b. Thus MYC-dependent miR-23b repression in myeloma cells may promote activation of oncogenic Sp1-mediated signaling, representing the first feed-forward loop with critical growth and survival role in myeloma.
- Published
- 2016
- Full Text
- View/download PDF
12. Características clínicas de adultos con Diabetes Mellitus 2 del consultorio del Hospital de Penco-Lirquén, Chile.
- Author
-
de la F. Karin, Noack, Marco, Mendoza E., María, Vergara A., and Natalia, Samur M.
- Subjects
DIABETES ,METABOLIC disorders ,HYPERGLYCEMIA ,CARDIOVASCULAR diseases ,TYPE 2 diabetes - Abstract
Copyright of Revista ANACEM is the property of Asociacion Nacional Cientifica de Estudiantes de Medicina de Chile and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2012
13. Características clínicas de pacientes ingresados con diagnóstico de insuficiencia cardiaca en un Hospital de la Familia y la Comunidad.
- Author
-
Marco, Mendoza E., de la F. Karin, Noack, Natalia, Samur M., and Marí a, Vergara A.
- Subjects
HEART failure ,HOSPITAL care ,PROGNOSIS ,RETROSPECTIVE studies ,SCIENTIFIC observation - Abstract
Copyright of Revista ANACEM is the property of Asociacion Nacional Cientifica de Estudiantes de Medicina de Chile and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2012
14. Quality of life in patients with advanced non-small cell lung cancer.
- Author
-
Bozcuk H, Dalmis B, Samur M, Ozdogan M, Artac M, and Savas B
- Published
- 2006
- Full Text
- View/download PDF
15. Primary lymphoma of bones.
- Author
-
Bayrakci, Kenan, Yildiz, Yusuf, Saglik, Yener, Altay, Murat, Ögüt, Hamit, Samur, Mustafa, Erekul, Selim, Bayrakci, K, Yildiz, Y, Saglik, Y, Altay, M, Ogüt, H, Samur, M, and Erekul, S
- Abstract
Copyright of International Orthopaedics is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2001
- Full Text
- View/download PDF
16. Prognostic Factors in Patients Treated with Radiotherapy for Brain Metastasis from Breast Carcinoma
- Author
-
Korcum, A.F., Aksu, G., Samur, M., and Ozdogan, M.
- Published
- 2008
- Full Text
- View/download PDF
17. 784 Results of the cyclophosphamide, adriamycine, vincristine, prednisolon (CHOP) ± bleomycine treatment and evaluation of prognostic factors in aggressive lymphomas
- Author
-
Dinçol, D., Içli, F., Akbulut, H., Samur, M., Karaoğuz, H., Demirkazik, A., and çay, F.
- Published
- 1995
- Full Text
- View/download PDF
18. Treatment Results of Chemoradiotherapy in Gastric Cancer
- Author
-
Korcum, A.F., Aksu, G., Ural, D., and Samur, M.
- Published
- 2008
- Full Text
- View/download PDF
19. Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications.
- Author
-
Letouzé E, Moreau P, Munshi N, Samur M, Minvielle S, and Touzeau C
- Subjects
- Humans, Drug Resistance, Neoplasm, Immunotherapy methods, Tumor Microenvironment immunology, Animals, Multiple Myeloma therapy, Multiple Myeloma immunology, T-Lymphocytes immunology, T-Lymphocytes metabolism, Antibodies, Bispecific therapeutic use, Antibodies, Bispecific pharmacology
- Abstract
Abstract: Bispecific T-cell engagers (TCEs) are revolutionizing patient care in multiple myeloma (MM). These monoclonal antibodies, that redirect T cells against cancer cells, are now approved for the treatment of triple-class exposed relapsed/refractory MM (RRMM). They are currently tested in earlier lines of the disease, including in first line. Yet, primary resistance occurs in about one-third of patients with RRMM, and most responders eventually develop acquired resistance. Understanding the mechanisms of resistance to bispecific TCE is thus essential to improve immunotherapies in MM. Here, we review recent studies investigating the clinical and molecular determinants of resistance to bispecific TCE. Resistance can arise from tumor-intrinsic or tumor-extrinsic mechanisms. Tumor-intrinsic resistance involves various alterations leading to the loss of the target antigen, such as chromosome deletions, point mutations, or epigenetic silencing. Loss of major histocompatibility complex (MHC) class I, preventing MHC class I: T-cell receptor (TCR) costimulatory signaling, was also reported. Tumor-extrinsic resistance involves abundant exhausted T-cell clones and several factors generating an immunosuppressive microenvironment. Importantly, some resistance mechanisms impair response to 1 TCE while preserving the efficacy of others. We next discuss the clinical implications of these findings. Monitoring the status of target antigens in tumor cells and their immune environment will be key to select the most appropriate TCE for each patient and to design combination and sequencing strategies for immunotherapy in MM., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
20. Redefining high risk multiple myeloma with an APOBEC/Inflammation-based classifier.
- Author
-
Grasedieck S, Panahi A, Jarvis MC, Borzooee F, Harris RS, Larijani M, Avet-Loiseau H, Samur M, Munshi N, Song K, Rouhi A, and Kuchenbauer F
- Subjects
- Humans, APOBEC Deaminases genetics, Biomarkers, Tumor, Prognosis, Multiple Myeloma pathology, Multiple Myeloma immunology, Inflammation pathology
- Published
- 2024
- Full Text
- View/download PDF
21. Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ+ T cells targeting multiple myeloma.
- Author
-
Bae J, Kitayama S, Herbert Z, Daheron L, Kurata K, Keskin DB, Livak K, Li S, Tarannum M, Romee R, Samur M, Munshi NC, Kaneko S, Ritz J, and Anderson KC
- Subjects
- Humans, B-Cell Maturation Antigen metabolism, T-Lymphocytes, Cytotoxic, Multiple Myeloma genetics, Multiple Myeloma therapy, Induced Pluripotent Stem Cells metabolism, Antineoplastic Agents metabolism, CD8 Antigens
- Abstract
Abstract: A major hurdle in adoptive T-cell therapy is cell exhaustion and failure to maintain antitumor responses. Here, we introduce an induced pluripotent stem cell (iPSC) strategy for reprogramming and revitalizing precursor exhausted B-cell maturation antigen (BCMA)-specific T cells to effectively target multiple myeloma (MM). Heteroclitic BCMA72-80 (YLMFLLRKI)-specific CD8+ memory cytotoxic T lymphocytes (CTL) were epigenetically reprogrammed to a pluripotent state, developed into hematopoietic progenitor cells (CD34+ CD43+/CD14- CD235a-), differentiated into the T-cell lineage and evaluated for their polyfunctional activities against MM. The final T-cell products demonstrated (1) mature CD8αβ+ memory phenotype, (2) high expression of activation or costimulatory molecules (CD38, CD28, and 41BB), (3) no expression of immune checkpoint and senescence markers (CTLA4, PD1, LAG3, and TIM3; CD57), and (4) robust proliferation and polyfunctional immune responses to MM. The BCMA-specific iPSC-T cells possessed a single T-cell receptor clonotype with cognate BCMA peptide recognition and specificity for targeting MM. RNA sequencing analyses revealed distinct genome-wide shifts and a distinctive transcriptional profile in selected iPSC clones, which can develop CD8αβ+ memory T cells. This includes a repertoire of gene regulators promoting T-cell lineage development, memory CTL activation, and immune response regulation (LCK, IL7R, 4-1BB, TRAIL, GZMB, FOXF1, and ITGA1). This study highlights the potential application of iPSC technology to an adaptive T-cell therapy protocol and identifies specific transcriptional patterns that could serve as a biomarker for selection of suitable iPSC clones for the successful development of antigen-specific CD8αβ+ memory T cells to improve the outcome in patients with MM., (© 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
22. Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.
- Author
-
Prabhala R, Pierceall WE, Samur M, Potluri LB, Hong K, Peluso T, Talluri S, Wang A, Katiki A, Vangala SD, Buonopane M, Bade V, Seah H, Krogman A, Derebail S, Fulciniti M, Lazo SB, Richardson P, Anderson K, Corre J, Avet-Loiseau H, Thakurta A, and Munshi N
- Abstract
Background: Multiple Myeloma (MM) patients exhibit dysregulated immune system, which is further weakened by chemotherapeutic agents. While cereblon-modulating agents, such as pomalidomide and lenalidomide, have been found to improve the immune profile, the efficacy of their impact in combination with other treatments is yet unknown., Methods: We conducted an immune-profiling of a longitudinal cohort of 366 peripheral blood samples from the CC4047-MM-007 (OPTIMISMM, NCT01734928) study. This study followed relapsed/refractory Multiple Myeloma (RRMM) patients who were treated with Velcade + dexamethasone (Vd), or Vd with pomalidomide (PVd). 366 blood samples from 186 patients were evaluated using multi-color flow cytometry at 3 timepoints: screening, day 8 of cycle 1, and cycle 3., Results: Among NK and NKT cell populations, adding pomalidomide showed no inhibition in the frequency of NK cells. When expression of double positivity for activation markers like, p46/NKG2D, on NK cells was higher than the median, PVd treated patients showed significantly better (p=0.05) progression-free survival (PFS) (additional 15 months) than patients with lower than the median expression of p46/NKG2D on NK cells. PVd treated patients who expressed CD158a/b below the median at cycle 1 demonstrated a significantly better PFS (more than 18months). Among B cell subtypes, PVd treatment significantly increased the abundance of B1b cells (p<0.05) and decreased Bregs (p<0.05) at day 8 of both cycle 1 and cycle 3 when compared to screening samples. Of all the B cell-markers evaluated among paired samples, a higher expression of MZB cells at day 8 of cycle 1 has resulted in enhanced PFS in PVd treated patients. Within T cells, pomalidomide treatment did not decrease the frequency of CD8 T cells when compared with screening samples. The higher the surface expression of OX-40 on CD8 T cells and the lower the expression of PD-1 and CD25 on CD4 T cells by PVd treatment resulted in improved PFS., Conclusion: The prognostic significance for the number of immune markers is only seen in the PVd arm and none of these immune markers exhibit prognostic values in the Vd arm. This study demonstrates the importance of the immunomodulatory effects and the therapeutic benefit of adding pomalidomide to Vd treatment., Competing Interests: Authors WP, KH, TP, AT, were employed by the company BMS, Bristol Myers Squibb. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Prabhala, Pierceall, Samur, Potluri, Hong, Peluso, Talluri, Wang, Katiki, Vangala, Buonopane, Bade, Seah, Krogman, Derebail, Fulciniti, Lazo, Richardson, Anderson, Corre, Avet-Loiseau, Thakurta and Munshi.)
- Published
- 2023
- Full Text
- View/download PDF
23. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.
- Author
-
Yao Y, Ng JF, Park WD, Samur M, Morelli E, Encinas Mayoral J, Chyra Z, Xu Y, Derebail S, Epstein C, Nabet B, Chesi M, Gray NS, Young RA, Kwiatkowski N, Mitsiades C, Anderson KC, Lin CY, Munshi NC, and Fulciniti M
- Subjects
- Animals, Mice, Cyclin-Dependent Kinases genetics, Cyclin-Dependent Kinases metabolism, Cyclin-Dependent Kinase-Activating Kinase, Multiple Myeloma genetics
- Abstract
Therapeutic targeting of CDK7 has proven beneficial in preclinical studies, yet the off-target effects of currently available CDK7 inhibitors make it difficult to pinpoint the exact mechanisms behind MM cell death mediated by CDK7 inhibition. Here, we show that CDK7 expression positively correlates with E2F and MYC transcriptional programs in cells from patients with multiple myeloma (MM); its selective targeting counteracts E2F activity via perturbation of the cyclin-dependent kinases/Rb axis and impairs MYC-regulated metabolic gene signatures translating into defects in glycolysis and reduced levels of lactate production in MM cells. CDK7 inhibition using the covalent small-molecule inhibitor YKL-5-124 elicits a strong therapeutic response with minimal effects on normal cells, and causes in vivo tumor regression, increasing survival in several mouse models of MM including a genetically engineered mouse model of MYC-dependent MM. Through its role as a critical cofactor and regulator of MYC and E2F activity, CDK7 is therefore a master regulator of oncogenic cellular programs supporting MM growth and survival, and a valuable therapeutic target providing rationale for development of YKL-5-124 for clinical use., (Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution.)
- Published
- 2023
- Full Text
- View/download PDF
24. The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM.
- Author
-
Stong N, Ortiz-Estévez M, Towfic F, Samur M, Agarwal A, Corre J, Flynt E, Munshi N, Avet-Loiseau H, and Thakurta A
- Subjects
- Humans, Base Sequence, Translocation, Genetic, Transcriptome, Multiple Myeloma metabolism
- Abstract
Although translocation events between chromosome 4 (NSD2 gene) and chromosome 14 (immunoglobulin heavy chain [IgH] locus) (t(4;14)) is considered high risk in newly diagnosed multiple myeloma (NDMM), only ∼30% to 40% of t(4;14) patients are clinically high risk. We generated and compared a large whole genome sequencing (WGS) and transcriptome (RNA sequencing) from 258 t(4;14) (n = 153 discovery, n = 105 replication) and 183 non-t(4;14) NDMM patients with associated clinical data. A landmark survival analysis indicated only ∼25% of t(4;14) patients had an overall survival (OS) <24 months, and a comparative analysis of the patient subgroups identified biomarkers associated with this poor outcome, including translocation breakpoints located in the NSD2 gene and expression of IgH-NSD2 fusion transcripts. Three breakpoints were identified and are designated as: "no-disruption" (upstream of NSD2), "early-disruption" (in the 5' UTR), and "late-disruption" (within the NSD2 gene). Our results show a significant difference in OS based on the location of DNA breakpoints (median OS 28.6 "late-disruption" vs 59.2 "early disruption" vs 75.1 months "no disruption"). These findings have been replicated in an independent replication dataset. Also, univariate and multivariate analysis suggest high-risk markers such as del17p, 1p independently contribute to poor outcome in t(4;14) MM patients., (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
25. In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations.
- Author
-
Lannes R, Samur M, Perrot A, Mazzotti C, Divoux M, Cazaubiel T, Leleu X, Schavgoulidze A, Chretien ML, Manier S, Adiko D, Orsini-Piocelle F, Lifermann F, Brechignac S, Gastaud L, Bouscary D, Macro M, Cleynen A, Mohty M, Munshi N, Corre J, and Avet-Loiseau H
- Subjects
- Humans, Retrospective Studies, Neoplasm Recurrence, Local genetics, Prognosis, Survival Analysis, Chromosome Aberrations, Multiple Myeloma diagnosis, Multiple Myeloma genetics, Multiple Myeloma therapy
- Abstract
Purpose: Multiple myeloma (MM) is characterized by copy number abnormalities (CNAs), some of which influence patient outcomes and are sometimes observed only at relapse(s), suggesting their acquisition during tumor evolution. However, the presence of micro-subclones may be missed in bulk analyses. Here, we use single-cell genomics to determine how often these high-risk events are missed at diagnosis and selected at relapse., Materials and Methods: We analyzed 81 patients with plasma cell dyscrasias using single-cell CNA sequencing. Sixty-six patients were selected at diagnosis, nine at first relapse, and six in presymptomatic stages. A total of 956 newly diagnosed patients with MM and patients with first relapse MM have been identified retrospectively with required cytogenetic data to evaluate enrichment of CNA risk events and survival impact., Results: A total of 52,176 MM cells were analyzed. Seventy-four patients (91%) had 2-16 subclones. Among these patients, 28.7% had a subclone with high-risk features (del(17p), del(1p32), and 1q gain) at diagnosis. In a patient with a subclonal 1q gain at diagnosis, we analyzed the diagnosis, postinduction, and first relapse samples, which showed a rise of the high-risk 1q gain subclone (16%, 70%, and 92%, respectively). In our clinical database, we found that the 1q gain frequency increased from 30.2% at diagnosis to 43.6% at relapse (odds ratio, 1.78; 95% CI, 1.58 to 2.00). We subsequently performed survival analyses, which showed that the progression-free and overall survival curves were superimposable between patients who had the 1q gain from diagnosis and those who seemingly acquired it at relapse. This strongly suggests that many patients had 1q gains at diagnosis in microclones that were missed by bulk analyses., Conclusion: These data suggest that identifying these scarce aggressive cells may necessitate more aggressive treatment as early as diagnosis to prevent them from becoming the dominant clone.
- Published
- 2023
- Full Text
- View/download PDF
26. Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma.
- Author
-
Merz M, Hu Q, Merz AMA, Wang J, Hutson N, Rondeau C, Celotto K, Belal A, Alberico R, Block AW, Mohammadpour H, Wallace PK, Tario J, Luce J, Glenn ST, Singh P, Samur M, Munshi N, Liu S, McCarthy PL, Wei L, and Hillengass J
- Subjects
- Humans, Bone Marrow pathology, Plasma Cells pathology, Tumor Microenvironment, Multiple Myeloma drug therapy, Neoplasms, Plasma Cell
- Abstract
Spatial heterogeneity is a common phenomenon in metastatic solid tumors and an evolving concept in multiple myeloma (MM). The interplay between malignant plasma cells (PCs) and the microenvironment has not yet been analyzed in MM. For this purpose, we performed bone marrow aspirates and imaging-guided biopsies of corresponding lesions in newly diagnosed MM (NDMM) and relapsed/refractory MM (RRMM) patients. PCs were isolated and subjected to whole-exome sequencing (WES). Non-PCs were studied with next-generation flow (NGF) and T-cell receptor sequencing (TCRseq) to analyze the connection between malignant and nonmalignant cells in the bone marrow and in lesions. Although we observed a strong overlap from WES, NGF, and TCRseq in patients with intramedullary disease, WES revealed significant spatial heterogeneity in patients with extramedullary disease. NGF showed significant immunosuppression in RRMM compared with NDMM as indicated by fewer myeloid dendritic cells, unswitched memory B cells, Th9 cells, and CD8 effector memory T cells but more natural killer and regulatory T cells. Additionally, fewer T-cell receptor (TCR) sequences were detected in RRMM compared with NDMM and healthy individuals. After induction therapy, TCR repertoire richness increased to levels of healthy individuals, and NGF showed more regulatory T cells and myeloid-derived suppressor cells, regardless of depth of response. Clinical significance of imaging-guided biopsies of lesions was demonstrated by detection of monoclonal PCs in patients without measurable residual disease (MRD) in aspirates from the iliac crest as well as identification of secondary primary malignancies in MRD- patients. Furthermore, site-specific clones with different drug susceptibilities and genetically defined high-risk features were detected by our workflow., (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
27. Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma.
- Author
-
Ansari-Pour N, Samur M, Flynt E, Gooding S, Towfic F, Stong N, Estevez MO, Mavrommatis K, Walker B, Morgan G, Munshi N, Avet-Loiseau H, and Thakurta A
- Subjects
- Humans, Dual Oxidases, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lenalidomide therapeutic use, Immunologic Factors therapeutic use, Dexamethasone therapeutic use, Multiple Myeloma drug therapy, Multiple Myeloma genetics, Multiple Myeloma pathology
- Abstract
Large-scale analyses of genomic data from patients with newly diagnosed multiple myeloma (ndMM) have been undertaken, however, large-scale analysis of relapsed/refractory MM (rrMM) has not been performed. We hypothesize that somatic variants chronicle the therapeutic exposures and clonal structure of myeloma from ndMM to rrMM stages. We generated whole-genome sequencing (WGS) data from 418 tumors (386 patients) derived from 6 rrMM clinical trials and compared them with WGS from 198 unrelated patients with ndMM in a population-based case-control fashion. We identified significantly enriched events at the rrMM stage, including drivers (DUOX2, EZH2, TP53), biallelic inactivation (TP53), noncoding mutations in bona fide drivers (TP53BP1, BLM), copy number aberrations (CNAs; 1qGain, 17pLOH), and double-hit events (Amp1q-ISS3, 1qGain-17p loss-of-heterozygosity). Mutational signature analysis identified a subclonal defective mismatch repair signature enriched in rrMM and highly active in high mutation burden tumors, a likely feature of therapy-associated expanding subclones. Further analysis focused on the association of genomic aberrations enriched at different stages of resistance to immunomodulatory agent (IMiD)-based therapy. This analysis revealed that TP53, DUOX2, 1qGain, and 17p loss-of-heterozygosity increased in prevalence from ndMM to lenalidomide resistant (LENR) to pomalidomide resistant (POMR) stages, whereas enrichment of MAML3 along with immunoglobulin lambda (IGL) and MYC translocations distinguished POM from the LEN subgroup. Genomic drivers associated with rrMM are those that confer clonal selective advantage under therapeutic pressure. Their role in therapy evasion should be further evaluated in longitudinal patient samples, to confirm these associations with the evolution of clinical resistance and to identify molecular subsets of rrMM for the development of targeted therapies., (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
28. Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk.
- Author
-
Ajore R, Niroula A, Pertesi M, Cafaro C, Thodberg M, Went M, Bao EL, Duran-Lozano L, Lopez de Lapuente Portilla A, Olafsdottir T, Ugidos-Damboriena N, Magnusson O, Samur M, Lareau CA, Halldorsson GH, Thorleifsson G, Norddahl GL, Gunnarsdottir K, Försti A, Goldschmidt H, Hemminki K, van Rhee F, Kimber S, Sperling AS, Kaiser M, Anderson K, Jonsdottir I, Munshi N, Rafnar T, Waage A, Weinhold N, Thorsteinsdottir U, Sankaran VG, Stefansson K, Houlston R, and Nilsson B
- Published
- 2022
- Full Text
- View/download PDF
29. Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities.
- Author
-
Giesen N, Paramasivam N, Toprak UH, Huebschmann D, Xu J, Uhrig S, Samur M, Bähr S, Fröhlich M, Mughal SS, Mai EK, Jauch A, Müller-Tidow C, Brors B, Munshi N, Goldschmidt H, Weinhold N, Schlesner M, and Raab MS
- Subjects
- Drug Resistance, Neoplasm genetics, Genomics, Humans, Mutation, Proteasome Inhibitors therapeutic use, Multiple Myeloma drug therapy, Multiple Myeloma genetics
- Abstract
The outcomes of patients with multiple myeloma (MM) refractory to immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) remain poor. In this study, we performed whole genome and transcriptome sequencing of 39 heavily pretreated relapsed/refractory MM (RRMM) patients to identify mechanisms of resistance and potential therapeutic targets. We observed a high mutational load and indications of increased genomic instability. Recurrently mutated genes in RRMM, which had not been previously reported or only observed at a lower frequency in newly diagnosed MM, included NRAS, BRAF, TP53, SLC4A7, MLLT4, EWSR1, HCFC2, and COPS3. We found multiple genomic regions with bi-allelic events affecting tumor suppressor genes and demonstrated a significant adverse impact of bi-allelic TP53 alterations on survival. With regard to potentially resistance conferring mutations, recurrently mutated gene networks included genes with relevance for PI and IMiD activity; the latter particularly affecting members of the Cereblon and the COP9 signalosome complex. We observed a major impact of signatures associated with exposure to melphalan or impaired DNA double-strand break homologous recombination repair in RRMM. The latter coincided with mutations in genes associated with PARP inhibitor sensitivity in 49% of RRMM patients; a finding with potential therapeutic implications. In conclusion, this comprehensive genomic characterization revealed a complex mutational and structural landscape in RRMM and highlights potential implications for therapeutic strategies.
- Published
- 2022
- Full Text
- View/download PDF
30. Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma.
- Author
-
Merz M, Merz AMA, Wang J, Wei L, Hu Q, Hutson N, Rondeau C, Celotto K, Belal A, Alberico R, Block AW, Mohammadpour H, Wallace PK, Tario J, Luce J, Glenn ST, Singh P, Herr MM, Hahn T, Samur M, Munshi N, Liu S, McCarthy PL, and Hillengass J
- Subjects
- Bone Diseases genetics, Bone Marrow metabolism, Cluster Analysis, Gene Expression Regulation, Neoplastic, Humans, Multiple Myeloma pathology, Plasma Cells, Exome Sequencing, Genetic Heterogeneity, Genomics, Multiple Myeloma genetics, Multiple Myeloma metabolism
- Abstract
Osteolytic lesions (OL) characterize symptomatic multiple myeloma. The mechanisms of how malignant plasma cells (PC) cause OL in one region while others show no signs of bone destruction despite subtotal infiltration remain unknown. We report on a single-cell RNA sequencing (scRNA-seq) study of PC obtained prospectively from random bone marrow aspirates (BM) and paired imaging-guided biopsies of OL. We analyze 148,630 PC from 24 different locations in 10 patients and observe vast inter- and intra-patient heterogeneity based on scRNA-seq analyses. Beyond the limited evidence for spatial heterogeneity from whole-exome sequencing, we find an additional layer of complexity by integrated analysis of anchored scRNA-seq datasets from the BM and OL. PC from OL are characterized by differentially expressed genes compared to PC from BM, including upregulation of genes associated with myeloma bone disease like DKK1, HGF and TIMP-1 as well as recurrent downregulation of JUN/FOS, DUSP1 and HBB. Assessment of PC from longitudinally collected samples reveals transcriptional changes after induction therapy. Our study contributes to the understanding of destructive myeloma bone disease., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
31. Functional dissection of inherited non-coding variation influencing multiple myeloma risk.
- Author
-
Ajore R, Niroula A, Pertesi M, Cafaro C, Thodberg M, Went M, Bao EL, Duran-Lozano L, Lopez de Lapuente Portilla A, Olafsdottir T, Ugidos-Damboriena N, Magnusson O, Samur M, Lareau CA, Halldorsson GH, Thorleifsson G, Norddahl GL, Gunnarsdottir K, Försti A, Goldschmidt H, Hemminki K, van Rhee F, Kimber S, Sperling AS, Kaiser M, Anderson K, Jonsdottir I, Munshi N, Rafnar T, Waage A, Weinhold N, Thorsteinsdottir U, Sankaran VG, Stefansson K, Houlston R, and Nilsson B
- Subjects
- Adaptor Proteins, Signal Transducing genetics, Adaptor Proteins, Signal Transducing immunology, Antineoplastic Combined Chemotherapy Protocols, B-Lymphocytes immunology, Base Sequence, Cell Cycle Proteins genetics, Cell Cycle Proteins immunology, Chromatin chemistry, Chromatin immunology, Chromosomal Proteins, Non-Histone genetics, Chromosomal Proteins, Non-Histone immunology, DNA, Intergenic immunology, Gene Expression Regulation, Neoplastic, Guanine Nucleotide Exchange Factors genetics, Guanine Nucleotide Exchange Factors immunology, Humans, Inheritance Patterns, Multiple Myeloma drug therapy, Multiple Myeloma immunology, Multiple Myeloma pathology, Neoplasm Proteins immunology, Plasma Cells immunology, Polymorphism, Genetic, Primary Cell Culture, Quantitative Trait Loci, Repressor Proteins genetics, Repressor Proteins immunology, Risk Assessment, Transcriptional Elongation Factors genetics, Transcriptional Elongation Factors immunology, B-Lymphocytes pathology, DNA, Intergenic genetics, Genetic Predisposition to Disease, Multiple Myeloma genetics, Neoplasm Proteins genetics, Plasma Cells pathology
- Abstract
Thousands of non-coding variants have been associated with increased risk of human diseases, yet the causal variants and their mechanisms-of-action remain obscure. In an integrative study combining massively parallel reporter assays (MPRA), expression analyses (eQTL, meQTL, PCHiC) and chromatin accessibility analyses in primary cells (caQTL), we investigate 1,039 variants associated with multiple myeloma (MM). We demonstrate that MM susceptibility is mediated by gene-regulatory changes in plasma cells and B-cells, and identify putative causal variants at six risk loci (SMARCD3, WAC, ELL2, CDCA7L, CEP120, and PREX1). Notably, three of these variants co-localize with significant plasma cell caQTLs, signaling the presence of causal activity at these precise genomic positions in an endogenous chromosomal context in vivo. Our results provide a systematic functional dissection of risk loci for a hematologic malignancy., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
32. Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13.
- Author
-
Song Y, Du T, Ray A, Chauhan K, Samur M, Munshi N, Chauhan D, and Anderson KC
- Subjects
- CRISPR-Cas Systems, HCT116 Cells, Humans, Intracellular Signaling Peptides and Proteins genetics, Multiple Myeloma genetics, Multiple Myeloma metabolism, Neoplasms genetics, Proteasome Endopeptidase Complex metabolism, Proteolysis, Proteomics, Ubiquitin metabolism, Intracellular Signaling Peptides and Proteins metabolism, Neoplasms metabolism
- Published
- 2021
- Full Text
- View/download PDF
33. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.
- Author
-
Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, Dimopoulos M, Kulakova M, Lam A, Hashim M, He J, Heeg B, Ukropec J, Vermeulen J, Cote S, and Bahlis N
- Subjects
- Cytogenetics, Humans, Neoplasm, Residual, Prognosis, Treatment Outcome, Multiple Myeloma diagnosis, Multiple Myeloma drug therapy
- Abstract
The prognostic value of minimal residual disease (MRD) for progression-free survival (PFS) and overall survival (OS) was evaluated in a large cohort of patients with multiple myeloma (MM) using a systematic literature review and meta-analysis. Medline and EMBASE databases were searched for articles published up to 8 June 2019, with no date limit on the indexed database. Clinical end points stratified by MRD status (positive or negative) were extracted, including hazard ratios (HRs) on PFS and OS, P values, and confidence intervals (CIs). HRs were estimated based on reconstructed patient-level data from published Kaplan-Meier curves. Forty-four eligible studies with PFS data from 8098 patients, and 23 studies with OS data from 4297 patients were identified to assess the association between MRD status and survival outcomes. Compared with MRD positivity, achieving MRD negativity improved PFS (HR, 0.33; 95% CI, 0.29-0.37; P < .001) and OS (HR, 0.45; 95% CI, 0.39-0.51; P < .001). MRD negativity was associated with significantly improved survival outcomes regardless of disease setting (newly diagnosed or relapsed/refractory MM), MRD sensitivity thresholds, cytogenetic risk, method of MRD assessment, depth of clinical response at the time of MRD measurement, and MRD assessment premaintenance and 12 months after start of maintenance therapy. The strong prognostic value of MRD negativity and its association with favorable outcomes in various disease and treatment settings sets the stage to adopt MRD as a treatment end point, including development of therapeutic strategies. This large meta-analysis confirms the utility of MRD as a relevant surrogate for PFS and OS in MM.
- Published
- 2020
- Full Text
- View/download PDF
34. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease.
- Author
-
Mason MJ, Schinke C, Eng CLP, Towfic F, Gruber F, Dervan A, White BS, Pratapa A, Guan Y, Chen H, Cui Y, Li B, Yu T, Chaibub Neto E, Mavrommatis K, Ortiz M, Lyzogubov V, Bisht K, Dai HY, Schmitz F, Flynt E, Dan Rozelle, Danziger SA, Ratushny A, Dalton WS, Goldschmidt H, Avet-Loiseau H, Samur M, Hayete B, Sonneveld P, Shain KH, Munshi N, Auclair D, Hose D, Morgan G, Trotter M, Bassett D, Goke J, Walker BA, Thakurta A, and Guinney J
- Subjects
- Biomarkers, Tumor genetics, Cell Cycle, Cell Proliferation, DNA-Binding Proteins genetics, Databases, Factual, Datasets as Topic, Humans, Multiple Myeloma genetics, Multiple Myeloma metabolism, Transcription Factors genetics, Tumor Cells, Cultured, Biomarkers, Tumor metabolism, Clinical Trials as Topic statistics & numerical data, DNA-Binding Proteins metabolism, Epigenesis, Genetic, Gene Expression Regulation, Neoplastic, Models, Statistical, Multiple Myeloma pathology, Transcription Factors metabolism
- Abstract
While the past decade has seen meaningful improvements in clinical outcomes for multiple myeloma patients, a subset of patients does not benefit from current therapeutics for unclear reasons. Many gene expression-based models of risk have been developed, but each model uses a different combination of genes and often involves assaying many genes making them difficult to implement. We organized the Multiple Myeloma DREAM Challenge, a crowdsourced effort to develop models of rapid progression in newly diagnosed myeloma patients and to benchmark these against previously published models. This effort lead to more robust predictors and found that incorporating specific demographic and clinical features improved gene expression-based models of high risk. Furthermore, post-challenge analysis identified a novel expression-based risk marker, PHF19, which has recently been found to have an important biological role in multiple myeloma. Lastly, we show that a simple four feature predictor composed of age, ISS, and expression of PHF19 and MMSET performs similarly to more complex models with many more gene expression features included.
- Published
- 2020
- Full Text
- View/download PDF
35. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.
- Author
-
Bar N, Costa F, Das R, Duffy A, Samur M, McCachren S, Gettinger SN, Neparidze N, Parker TL, Bailur JK, Pendleton K, Bajpai R, Zhang L, Xu ML, Anderson T, Giuliani N, Nooka A, Cho HJ, Raval A, Shanmugam M, Dhodapkar KM, and Dhodapkar MV
- Subjects
- Antibodies, Monoclonal immunology, Antibodies, Monoclonal therapeutic use, Antigen-Presenting Cells immunology, Humans, Immunotherapy methods, Inflammation drug therapy, Lung Neoplasms drug therapy, Lung Neoplasms immunology, Multiple Myeloma immunology, Programmed Cell Death 1 Receptor drug effects, Antibodies, Monoclonal, Humanized therapeutic use, B7-H1 Antigen immunology, Multiple Myeloma drug therapy
- Abstract
BACKGROUNDPD-1 and PD-L1 have been studied interchangeably in the clinic as checkpoints to reinvigorate T cells in diverse tumor types. Data for biologic effects of checkpoint blockade in human premalignancy are limited.METHODSWe analyzed the immunologic effects of PD-L1 blockade in a clinical trial of atezolizumab in patients with asymptomatic multiple myeloma (AMM), a precursor to clinical malignancy. Genomic signatures of PD-L1 blockade in purified monocytes and T cells in vivo were also compared with those following PD-1 blockade in lung cancer patients. Effects of PD-L1 blockade on monocyte-derived DCs were analyzed to better understand its effects on myeloid antigen-presenting cells.RESULTSIn contrast to anti-PD-1 therapy, anti-PD-L1 therapy led to a distinct inflammatory signature in CD14+ monocytes and increase in myeloid-derived cytokines (e.g., IL-18) in vivo. Treatment of AMM patients with atezolizumab led to rapid activation and expansion of circulating myeloid cells, which persisted in the BM. Blockade of PD-L1 on purified monocyte-derived DCs led to rapid inflammasome activation and synergized with CD40L-driven DC maturation, leading to greater antigen-specific T cell expansion.CONCLUSIONThese data show that PD-L1 blockade leads to distinct systemic immunologic effects compared with PD-1 blockade in vivo in humans, particularly manifest as rapid myeloid activation. These findings also suggest an additional role for PD-L1 as a checkpoint for regulating inflammatory phenotype of myeloid cells and antigen presentation in DCs, which may be harnessed to improve PD-L1-based combination therapies.TRIAL REGISTRATIONNCT02784483.FUNDINGThis work is supported, in part, by funds from NIH/NCI (NCI CA197603, CA238471, and CA208328).
- Published
- 2020
- Full Text
- View/download PDF
36. Adaptation and validation of the Compliance with Standard Precautions Scale amongst nurses in Turkey.
- Author
-
Samur M, Seren Intepeler S, and Lam SC
- Subjects
- Adult, Female, Humans, Infection Control, Male, Occupational Health, Patient Safety, Reproducibility of Results, Surveys and Questionnaires, Translations, Turkey, Guideline Adherence, Nursing Staff psychology, Psychometrics
- Abstract
Aims: To adapt and psychometrically test the Compliance with Standard Precautions Scale for use by Turkish nurses., Background: Measurement of standard precautions compliance is important to manage the safety of both patients and health care teams., Methods: This two-phase methodological study employed a correlational design with repeated measures. In phase one, the scale's adaptation, including translation, semantic equivalence, content and face validity, was implemented. In phase two, internal consistency and stability were used to examine the reliability of the scale. Construct validity was tested using the Rasch rating scale model. This study was conducted by recruiting 411 nurses from three different hospitals between September 2015 and September 2016., Results: Adaptation results showed that the Turkish version of the Compliance with Standard Precautions Scale (CSPS-T) is adequate for linguistic and content validation. The content validity index and comprehensibility of the scale were similarly satisfactory. The reliability of the CSPS-T was examined by Cronbach's alpha, corrected item-total correlations and intraclass correlation coefficient, and good results were obtained. The Rasch model showed that all items were compatible with the model. Whereas Item 4 was the most difficult, Item 10 was the easiest., Conclusion: The CSPS-T is a reliable and valid tool for assessing compliance with standard precautions amongst Turkish nurses., (© 2020 John Wiley & Sons Australia, Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
37. Food restriction reconfigures naïve and learned choice behavior in Drosophila larvae.
- Author
-
Brünner B, Saumweber J, Samur M, Weber D, Schumann I, Mahishi D, Rohwedder A, and Thum AS
- Subjects
- Animals, Drosophila melanogaster, Larva physiology, Memory physiology, Appetitive Behavior physiology, Choice Behavior physiology, Learning physiology
- Abstract
In many animals, the establishment and expression of food-related memory is limited by the presence of food and promoted by its absence, implying that this behavior is driven by motivation. In the past, this has already been demonstrated in various insects including honeybees and adult Drosophila . For Drosophila larvae, which are characterized by an immense growth and the resulting need for constant food intake, however, knowledge is rather limited. Accordingly, we have analyzed whether starvation modulates larval memory formation or expression after appetitive classical olfactory conditioning, in which an odor is associated with a sugar reward. We show that odor-sugar memory of starved larvae lasts longer than in fed larvae, although the initial performance is comparable. 80 minutes after odor fructose conditioning, only starved but not fed larvae show a reliable odor-fructose memory. This is likely due to a specific increase in the stability of anesthesia-resistant memory (ARM). Furthermore, we observe that starved larvae, in contrast to fed ones, prefer sugars that offer a nutritional benefit in addition to their sweetness. Taken together our work shows that Drosophila larvae adjust the expression of learned and naïve choice behaviors in the absence of food. These effects are only short-lasting probably due to their lifestyle and their higher internal motivation to feed. In the future, the extensive use of established genetic tools will allow us to identify development-specific differences arising at the neuronal and molecular level.
- Published
- 2020
- Full Text
- View/download PDF
38. Author Correction: MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
- Author
-
Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, and Kufe D
- Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2020
- Full Text
- View/download PDF
39. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
- Author
-
Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, and Kufe D
- Subjects
- Animals, Aurora Kinase A metabolism, Basic Helix-Loop-Helix Transcription Factors metabolism, Carcinogenesis genetics, Carcinoma, Neuroendocrine genetics, Cell Line, Tumor, Enhancer of Zeste Homolog 2 Protein metabolism, Gene Expression Regulation, Neoplastic, Homeodomain Proteins metabolism, Humans, Kruppel-Like Factor 4, Kruppel-Like Transcription Factors metabolism, Male, Mice, Mice, Nude, Mucin-1 genetics, N-Myc Proto-Oncogene Protein metabolism, Neoplastic Stem Cells metabolism, Octamer Transcription Factor-3 metabolism, POU Domain Factors metabolism, Prostate pathology, Prostatic Neoplasms genetics, Prostatic Neoplasms, Castration-Resistant genetics, Prostatic Neoplasms, Castration-Resistant metabolism, Proto-Oncogene Proteins c-myc, SOXB1 Transcription Factors metabolism, Signal Transduction, Synaptophysin metabolism, Tumor Suppressor Protein p53 metabolism, Carcinoma, Neuroendocrine metabolism, Disease Progression, Mucin-1 metabolism, Neuronal Plasticity physiology, Prostatic Neoplasms metabolism
- Abstract
Neuroendocrine prostate cancer (NEPC) is an aggressive malignancy with no effective targeted therapies. The oncogenic MUC1-C protein is overexpressed in castration-resistant prostate cancer (CRPC) and NEPC, but its specific role is unknown. Here, we demonstrate that upregulation of MUC1-C in androgen-dependent PC cells suppresses androgen receptor (AR) axis signaling and induces the neural BRN2 transcription factor. MUC1-C activates a MYC→BRN2 pathway in association with induction of MYCN, EZH2 and NE differentiation markers (ASCL1, AURKA and SYP) linked to NEPC progression. Moreover, MUC1-C suppresses the p53 pathway, induces the Yamanaka pluripotency factors (OCT4, SOX2, KLF4 and MYC) and drives stemness. Targeting MUC1-C decreases PC self-renewal capacity and tumorigenicity, suggesting a potential therapeutic approach for CRPC and NEPC. In PC tissues, MUC1 expression associates with suppression of AR signaling and increases in BRN2 expression and NEPC score. These results highlight MUC1-C as a master effector of lineage plasticity driving progression to NEPC.
- Published
- 2020
- Full Text
- View/download PDF
40. Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling.
- Author
-
Ho M, Chen T, Liu J, Dowling P, Hideshima T, Zhang L, Morelli E, Camci-Unal G, Wu X, Tai YT, Wen K, Samur M, Schlossman RL, Mazitschek R, Kavanagh EL, Lindsay S, Harada T, McCann A, Anderson KC, O'Gorman P, and Bianchi G
- Subjects
- Animals, Bone Marrow metabolism, Cell Proliferation physiology, Endothelial Cells enzymology, Exosomes metabolism, Heterografts, Humans, Interleukin-6 metabolism, Mice, Multiple Myeloma pathology, Signal Transduction physiology, Histone Deacetylases metabolism, Mesenchymal Stem Cells enzymology, Multiple Myeloma enzymology, Tumor Microenvironment physiology
- Abstract
Multiple myeloma (MM) is an incurable cancer that derives pro-survival/proliferative signals from the bone marrow (BM) niche. Novel agents targeting not only cancer cells, but also the BM-niche have shown the greatest activity in MM. Histone deacetylases (HDACs) are therapeutic targets in MM and we previously showed that HDAC3 inhibition decreases MM proliferation both alone and in co-culture with bone marrow stromal cells (BMSC). In this study, we investigate the effects of HDAC3 targeting in BMSCs. Using both BMSC lines as well as patient-derived BMSCs, we show that HDAC3 expression in BMSCs can be induced by co-culture with MM cells. Knock-out (KO), knock-down (KD), and pharmacologic inhibition of HDAC3 in BMSCs results in decreased MM cell proliferation; including in autologous cultures of patient MM cells with BMSCs. We identified both quantitative and qualitative changes in exosomes and exosomal miRNA, as well as inhibition of IL-6 trans-signaling, as molecular mechanisms mediating anti-MM activity. Furthermore, we show that HDAC3-KD in BM endothelial cells decreases neoangiogenesis, consistent with a broad effect of HDAC3 targeting in the BM-niche. Our results therefore support the clinical development of HDAC3 inhibitors based not only on their direct anti-MM effects, but also their modulation of the BM microenvironment.
- Published
- 2020
- Full Text
- View/download PDF
41. MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells.
- Author
-
Rajabi H, Hata T, Li W, Long MD, Hu Q, Liu S, Raina D, Kui L, Yasumizu Y, Hong D, Samur M, and Kufe D
- Subjects
- Carcinoma pathology, Cell Line, Tumor, Humans, Carcinoma metabolism, Gene Expression Regulation, Neoplastic physiology, Mucin-1 metabolism, Tumor Suppressor Proteins metabolism
- Abstract
RASSF1A encodes a tumor suppressor that inhibits the RAS→RAF→MEK→ERK pathway and is one of the most frequently inactivated genes in human cancers. MUC1-C is an oncogenic effector of the cancer cell epigenome that is overexpressed in diverse carcinomas. We show here that MUC1-C represses RASSF1A expression in KRAS wild-type and mutant cancer cells. Mechanistically, MUC1-C occupies the RASSF1A promoter in a complex with the ZEB1 transcriptional repressor. In turn, MUC1-C/ZEB1 complexes recruit DNA methyltransferase 3b (DNMT3b) to the CpG island in the RASSF1A promoter. Targeting MUC1-C, ZEB1, and DNMT3b thereby decreases methylation of the CpG island and derepresses RASSF1A transcription. We also show that targeting MUC1-C regulates KRAS signaling, as evidenced by RNA-seq analysis, and decreases MEK/ERK activation, which is of importance for RAS-mediated tumorigenicity. These findings define a previously unrecognized role for MUC1-C in suppression of RASSF1A and support targeting MUC1-C as an approach for inhibiting MEK→ERK signaling.
- Published
- 2019
- Full Text
- View/download PDF
42. Correction: MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells.
- Author
-
Rajabi H, Hata T, Li W, Long MD, Hu Q, Liu S, Raina D, Kui L, Yasumizu Y, Hong D, Samur M, and Kufe D
- Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2019
- Full Text
- View/download PDF
43. Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer.
- Author
-
Hata T, Rajabi H, Yamamoto M, Jin C, Ahmad R, Zhang Y, Kui L, Li W, Yasumizu Y, Hong D, Miyo M, Hiraki M, Maeda T, Suzuki Y, Takahashi H, Samur M, and Kufe D
- Subjects
- Cell Line, Tumor, Cell Self Renewal drug effects, Drug Resistance, Neoplasm, Epithelial-Mesenchymal Transition, Female, Gene Expression Regulation, Neoplastic drug effects, Humans, Neoplastic Stem Cells metabolism, Neoplastic Stem Cells pathology, Nuclear Proteins genetics, Paclitaxel pharmacology, Paclitaxel therapeutic use, Signal Transduction, Triple Negative Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms genetics, Triple Negative Breast Neoplasms pathology, Twist-Related Protein 1 genetics, Mucin-1 metabolism, Nuclear Proteins metabolism, Triple Negative Breast Neoplasms metabolism, Twist-Related Protein 1 metabolism
- Abstract
The oncogenic MUC1-C protein and the TWIST1 epithelial-mesenchymal transition transcription factor (EMT-TF) are aberrantly expressed in triple-negative breast cancer (TNBC) cells. However, there is no known association between MUC1-C and TWIST1 in TNBC or other cancer cells. Here, we show that MUC1-C activates STAT3, and that MUC1-C and pSTAT3 drive induction of the TWIST1 gene. In turn, MUC1-C binds directly to TWIST1, and MUC1-C/TWIST1 complexes activate MUC1-C expression in an autoinductive circuit. The functional significance of the MUC1-C/TWIST1 circuit is supported by the demonstration that this pathway is sufficient for driving (i) the EMT-TFs, ZEB1 and SNAIL, (ii) multiple genes in the EMT program as determined by RNA-seq, and (iii) the capacity for cell invasion. We also demonstrate that the MUC1-C/TWIST1 circuit drives (i) expression of the stem cell markers SOX2, BMI1, ALDH1, and CD44, (ii) self-renewal capacity, and (iii) tumorigenicity. In concert with these results, we show that MUC1-C and TWIST1 also drive EMT and stemness in association with acquired paclitaxel (PTX) resistance. Of potential therapeutic importance, targeting MUC1-C and thereby TWIST1 reverses the PTX refractory phenotype as evidenced by synergistic activity with PTX against drug-resistant cells. These findings uncover a master role for MUC1-C in driving the induction of TWIST1, EMT, stemness, and drug resistance, and support MUC1-C as a highly attractive target for inhibiting TNBC plasticity and progression., (©2019 American Association for Cancer Research.)
- Published
- 2019
- Full Text
- View/download PDF
44. Nurses' view of their work environment, health and safety: A qualitative study.
- Author
-
Samur M and Seren Intepeler S
- Subjects
- Adult, Attitude of Health Personnel, Female, Focus Groups methods, Humans, Job Satisfaction, Male, Middle Aged, Nurses statistics & numerical data, Qualitative Research, Workplace psychology, Workplace statistics & numerical data, Health Status, Nurses psychology, Workplace standards
- Abstract
Aim: This study aims to determine the nurses' view of the work environment on nurses' health and safety., Background: The creation of positive work environments has become one of the key determining factors to improve nurse outcomes., Methods: The research, a qualitative descriptive design, was conducted between January and October 2017 with a total of 17 nurses. Nurses were selected for the study using the purposive sampling method, and in-depth interviews were carried out with these nurses under the guidance of a semi-structured interview form. Thematic analysis was conducted to analyse the interviews., Results: In line with the views of nurses, two main themes as "physical environment regulations" and "administrative arrangements" and six sub-themes (room structures and plans, hygiene conditions, lack of materials, occupational precautions, the attitude of the managers, team collaboration and communication) were determined as the nurses' health and safety issues on their work environment., Conclusions: Personal, administrative and institutional improvements are needed, especially for the prevention of work accidents and injuries., Implications for Nursing Management: The study results will serve to guide legislators and upper-middle-sub-level managers in developing interventions to create supportive work environments for the health and safety of nurses., (© 2019 John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
45. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8 + cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy.
- Author
-
Bae J, Samur M, Richardson P, Munshi NC, and Anderson KC
- Subjects
- Cell Line, Tumor, Humans, Immunotherapy, Adoptive methods, Vaccination methods, B-Cell Maturation Antigen immunology, CD8-Positive T-Lymphocytes immunology, Cytotoxicity, Immunologic immunology, Multiple Myeloma immunology, Multiple Myeloma therapy, T-Lymphocytes, Cytotoxic immunology
- Abstract
To expand the breadth and extent of current multiple myeloma (MM)-specific immunotherapy, we have identified various antigens on CD138
+ tumor cells from newly diagnosed MM patients (n = 616) and confirmed B-cell maturation antigen (BCMA) as a key myeloma-associated antigen. The aim of this study is to target the BCMA, which promotes MM cell growth and survival, by generating BCMA-specific memory CD8+ CTL that mediate effective and long-lasting immunity against MM. Here we report the identification of novel engineered peptides specific to BCMA, BCMA72-80 (YLMFLLRKI), and BCMA54-62 (YILWTCLGL), which display improved affinity/stability to HLA-A2 compared to their native peptides and induce highly functional BCMA-specific CTL with increased activation (CD38, CD69) and co-stimulatory (CD40L, OX40, GITR) molecule expression. Importantly, the heteroclitic BCMA72-80 specific CTL demonstrated poly-functional Th1-specific immune activities [IFN-γ/IL-2/TNF-α production, proliferation, cytotoxicity] against MM, which were correlated with expansion of Tetramer+ and memory CD8+ CTL. Additionally, heteroclitic BCMA72-80 specific CTL treated with anti-OX40 (immune agonist) or anti-LAG-3 (checkpoint inhibitor) display increased immune function, mainly by central memory CTL. These results provide the framework for clinical application of heteroclitic BCMA72-80 peptide, alone and in combination with anti-LAG3 and/or anti-OX40 therapy, in vaccination and/or adoptive immunotherapeutic strategies to generate long-lasting anti-tumor immunity in patients with MM or other BCMA expressing tumors.- Published
- 2019
- Full Text
- View/download PDF
46. Nurses' identification and reporting of medication errors.
- Author
-
Dirik HF, Samur M, Seren Intepeler S, and Hewison A
- Subjects
- Female, Hospitals, University, Humans, Male, Medication Errors psychology, Patient Safety, Surveys and Questionnaires, Turkey, Medication Errors nursing, Nursing Staff, Hospital statistics & numerical data, Truth Disclosure
- Abstract
Aims and Objectives: To investigate hospital nurses' involvement in the identification and reporting of medication errors in Turkey., Background: Medication safety is an international priority, and medication error identification and reporting are essential for patient safety., Design: A descriptive survey design consistent with the STROBE guidelines was used., Methods: The participants were 135 nurses employed in a university hospital in Turkey. The survey instrument included 18 sample cases and respondents identified whether errors had been made and how they should be reported. Descriptive statistics were analysed using the chi-square and Fisher's exact tests., Results: The sample case of "Patient given 10 mg morphine sulphate instead of 1.0 mg of morphine sulphate" was defined as a medication error by 97% of respondents, whereas the sample case of "Omitting oral/IV antibiotics because of the need to take the patient out for X-rays for 3 hr" was defined as a medication error by only 32.1%. It was found that eight sample cases (omitting antibiotics, diluting norodol drops with saline, giving aspirin preprandially, injecting clexane before colonoscopy, giving an analgesic at the nurse's discretion, dispensing undiluted morphine, preparing dobutamine instead of dopamine and administering enteral nutrition intravenously) were assessed as errors and reported, although there were significant statistical differences between the identification and reporting of these errors., Conclusion: Nurses are able to identify medication errors, but are reluctant to report them. Fear of the consequences was the main reason given for not reporting medication errors. When errors are reported, it is likely to be to physicians., Relevance to Clinical Practice: The development of a commonly agreed definition of a medication error, along with clear and robust reporting mechanisms, would be a positive step towards increasing patient safety. Staff reporting medication errors should be supported, not punished, and the information provided used to improve the system., (© 2018 John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
47. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
- Author
-
Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, and Morgan G
- Subjects
- Humans, Multiple Myeloma diagnosis, Prognosis, Risk Factors, Survival Rate, Biomarkers, Tumor genetics, Chromosome Aberrations, Genome, Human, Genomics methods, High-Throughput Nucleotide Sequencing methods, Multiple Myeloma genetics
- Abstract
Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used to identify high-risk patients, each of which has significant weaknesses. Inclusion of molecular features into risk stratification could resolve the current challenges. In a genome-wide analysis of the largest set of molecular and clinical data established to date from NDMM, as part of the Myeloma Genome Project, we have defined DNA drivers of aggressive clinical behavior. Whole-genome and exome data from 1273 NDMM patients identified genetic factors that contribute significantly to progression free survival (PFS) and overall survival (OS) (cumulative R
2 = 18.4% and 25.2%, respectively). Integrating DNA drivers and clinical data into a Cox model using 784 patients with ISS, age, PFS, OS, and genomic data, the model has a cumlative R2 of 34.3% for PFS and 46.5% for OS. A high-risk subgroup was defined by recursive partitioning using either a) bi-allelic TP53 inactivation or b) amplification (≥4 copies) of CKS1B (1q21) on the background of International Staging System III, comprising 6.1% of the population (median PFS = 15.4 months; OS = 20.7 months) that was validated in an independent dataset. Double-Hit patients have a dire prognosis despite modern therapies and should be considered for novel therapeutic approaches.- Published
- 2019
- Full Text
- View/download PDF
48. Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14).
- Author
-
Cleynen A, Samur M, Perrot A, Buisson L, Maheo S, Fulciniti M, Attal M, Munshi N, Avet-Loiseau H, and Corre J
- Subjects
- Disease-Free Survival, Female, Humans, Male, Survival Rate, Chromosomes, Human, Pair 11 genetics, Chromosomes, Human, Pair 11 metabolism, Chromosomes, Human, Pair 14 genetics, Chromosomes, Human, Pair 14 metabolism, Multiple Myeloma genetics, Multiple Myeloma mortality, Multiple Myeloma pathology, Proto-Oncogene Proteins c-bcl-2 genetics, Proto-Oncogene Proteins c-bcl-2 metabolism, Translocation, Genetic, bcl-X Protein genetics, bcl-X Protein metabolism
- Published
- 2018
- Full Text
- View/download PDF
49. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
- Author
-
Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, and Morgan GJ
- Subjects
- Clone Cells, DNA Mutational Analysis, DNA, Neoplasm genetics, Datasets as Topic, Gene Dosage, Genome-Wide Association Study, Genomic Instability, Genomics, Humans, Loss of Heterozygosity, Multiple Myeloma pathology, Mutation, Prognosis, Translocation, Genetic, Treatment Outcome, Exome Sequencing, Gene Expression Regulation, Neoplastic, Multiple Myeloma genetics, Mutagenesis, Oncogenes
- Abstract
Understanding the profile of oncogene and tumor suppressor gene mutations with their interactions and impact on the prognosis of multiple myeloma (MM) can improve the definition of disease subsets and identify pathways important in disease pathobiology. Using integrated genomics of 1273 newly diagnosed patients with MM, we identified 63 driver genes, some of which are novel, including IDH1 , IDH2 , HUWE1 , KLHL6 , and PTPN11 Oncogene mutations are significantly more clonal than tumor suppressor mutations, indicating they may exert a bigger selective pressure. Patients with more driver gene abnormalities are associated with worse outcomes, as are identified mechanisms of genomic instability. Oncogenic dependencies were identified between mutations in driver genes, common regions of copy number change, and primary translocation and hyperdiploidy events. These dependencies included associations with t(4;14) and mutations in FGFR3 , DIS3 , and PRKD2 ; t(11;14) with mutations in CCND1 and IRF4 ; t(14;16) with mutations in MAF , BRAF , DIS3 , and ATM ; and hyperdiploidy with gain 11q, mutations in FAM46C , and MYC rearrangements. These associations indicate that the genomic landscape of myeloma is predetermined by the primary events upon which further dependencies are built, giving rise to a nonrandom accumulation of genetic hits. Understanding these dependencies may elucidate potential evolutionary patterns and lead to better treatment regimens., (© 2018 by The American Society of Hematology.)
- Published
- 2018
- Full Text
- View/download PDF
50. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.
- Author
-
Maura F, Petljak M, Lionetti M, Cifola I, Liang W, Pinatel E, Alexandrov LB, Fullam A, Martincorena I, Dawson KJ, Angelopoulos N, Samur MK, Szalat R, Zamora J, Tarpey P, Davies H, Corradini P, Anderson KC, Minvielle S, Neri A, Avet-Loiseau H, Keats J, Campbell PJ, Munshi NC, and Bolli N
- Subjects
- Cell Line, Tumor, Humans, Prognosis, APOBEC Deaminases genetics, Leukemia, Plasma Cell genetics, Multiple Myeloma genetics, Mutation genetics, Paraproteinemias genetics
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.